Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection
Status:
Withdrawn
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
COVID-19 outcomes are worse in male patients. Androgen signaling, therefore, is a target for
clinical exploration. TMPRSS2 is a membrane protease required for COVID pathogenesis that is
regulated by androgens. Blocking TMPRSS2 with bicalutamide may reduce viral replication and
improve the clinical outcome. Therefore, the study proposes to test bicalutamide at 150 mg
oral daily dosing in a double-blind placebo-controlled randomized trial in male patients with
early symptomatic COVID-19 disease.